Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Type:
Application
Filed:
December 21, 2016
Publication date:
April 27, 2017
Applicants:
OSE Immunotherapeutics, Institut National de la Sante et de la Recherche M edicale (INSERM)
Inventors:
Caroline Mary, Nicolas Poirier, Bernard Vanhove
Abstract: The invention relates to a HIP/PAP protein or to one of the derivatives thereof for use thereof for treating or preventing insulin resistance in non-insulin dependent subjects.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
April 25, 2017
Assignees:
ALFACT INNOVATION, INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS SUD, UNIVERSITE PARIS DIDEROT—PARIS 7
Inventors:
Fabrizio Andreelli, Paul Amouyal, Christophe Magnan, Celine Cruciani-Guglielmacci, Jamila Vaivre, Marion Darnaud, Laure Jamot, Christian Brechot, Gilles Amouyal
Abstract: A cell carrying microsphere composition, wherein the microsphere composition comprises a microspheric core comprising a triblock copolymer matrix A-B-A wherein A is selected from poly(lactide-co-glycolide) (PLGA) or polylactide (PLA) and B is poloxamer or poloxamine, wherein the microspheric core is coated with a cell adhesion coating and further comprises whole cells or cell fragments bonded to the cell adhesion coating, a process for the preparation of a cell carrying microsphere composition, and applications thereof.
Type:
Grant
Filed:
March 29, 2013
Date of Patent:
April 25, 2017
Assignee:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Inventors:
Marie Morille, Van-Thanh Tran, Xavier Garric, Jean Coudane, Marie-Claire Venier-Julienne, Claudia Montero-Menei
Abstract: The invention relates to a new group of snake venom basic protease inhibitors having vasopressin-2 receptor antagonist activity that can be used in therapy, diagnosis, medical imaging, drug screening and research.
Type:
Grant
Filed:
September 17, 2013
Date of Patent:
April 25, 2017
Assignees:
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITY OF REGENSBURG, UNIVERSITY DE LIEGE
Inventors:
Nicolas Gilles, Denis Servent, Loïc Quinton, Helen Reinfrank, Ralph Witzgall, Bernard Mouillac, Christiane Mendre
Abstract: Bioprinting station (1) comprising:—a Bioprinting device (4) adapted to deposit a pattern of biological material (2) onto an area of interest (3a) of a substrate (3),—an imaging system (15) adapted to acquire an image of the substrate (3) and to reveal on the acquired image the area of interest (3a) with respect to a remaining part (3b) of the substrate (3), the acquired image of the substrate (3) being processed so as to detect the revealed area of interest (3a) on the acquired image and to determine the pattern corresponding to the area of interest (3a) detected on the acquired image.
Type:
Grant
Filed:
April 22, 2015
Date of Patent:
April 25, 2017
Assignee:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: The present invention relates to pharmaceutical compositions comprising sodium thiosulphate dispersed in a hydrophile-in-lipophile emulsion, and the use thereof for topical administration for the treatment of an ectopic calcification and/or of the consequences thereof in an individual, the sodium thiosulphate being in the form of a pharmaceutical composition comprising, in addition, a hydrophile-in-lipophile emulsion. The invention also relates to a method for preparing these pharmaceutical compositions.
Type:
Grant
Filed:
May 10, 2013
Date of Patent:
April 25, 2017
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LIMOGES, CHU DE LIMOGES, UNIVERSITE PARIS-SUD
Inventors:
Voa Ratsimbazafy, Jeremy Jost, Vincent Guigonis, Eric Caudron
Abstract: The present invention relates to chitosan hydrogel microparticles of a median size d50 comprised between 1 and 500 ?m (obtained from a number distribution), the chitosan having a degree of acetylation of less than equal to 20% and its concentration in the hydrogel being comprised between 0.25 and 5% by weight based on a total weight of the hydrogel, for use in neuron regeneration and/or in the repair of the nervous system, advantageously of the central nervous system, and/or in the grafting of neurons and/or in the treatment of neurodegenerative diseases and/or in the treatment of paralyses. It also relates to an implant comprising an aqueous suspension of microparticles mixed with Schwann cells and/or stem cells and/or trophic factors.
Type:
Grant
Filed:
July 16, 2013
Date of Patent:
April 18, 2017
Assignees:
UNIVERSITE CLAUDE BERNARD LYON I, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, UNIVERSITE JEAN MONNET, SAINT ETIENNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
Inventors:
Fatiha Nothias, Sylvia Soares, Laurent David, Alexandra Montembault
Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogs thereof and polyepitopes containing such epitopes and/or analogs. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
Type:
Grant
Filed:
August 26, 2013
Date of Patent:
April 18, 2017
Assignees:
INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Abstract: The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
Type:
Application
Filed:
June 9, 2015
Publication date:
April 13, 2017
Applicant:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DA LA RECHERCHE MÉDICALE)
Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Grant
Filed:
October 15, 2010
Date of Patent:
April 4, 2017
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (CNRS), LES LABORATOIRES SERVIER
Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
Type:
Grant
Filed:
January 29, 2010
Date of Patent:
March 28, 2017
Assignees:
UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
Type:
Grant
Filed:
May 24, 2013
Date of Patent:
March 28, 2017
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
Type:
Grant
Filed:
December 29, 2011
Date of Patent:
March 21, 2017
Assignees:
Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE
Inventors:
Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
Abstract: Provided herein are methods for expressing a polynucleotide of interest in the retina of a subject. In particular, a method for expressing a polynucleotide of interest in the retina of a subject comprising the step consisting of injecting into the vitreous an amount of a vector containing the polynucleotide of interest in combination with an amount of an inhibitor of Dp71 expression is provided.
Type:
Grant
Filed:
June 27, 2014
Date of Patent:
March 21, 2017
Assignees:
INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Deniz Dalkara, Alvaro Rendon Fuentes, Jose Alain Sahel, Ophelie Vacca
Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.
Type:
Application
Filed:
December 16, 2014
Publication date:
March 16, 2017
Applicant:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: The invention relates to the field of cell therapy, particularly NK cell mediated therapy. The present invention relates to a method of producing an ex vivo population of cells, preferably NK cells, from at least two umbilical cord blood units (UCB units), or fraction thereof containing said cells, by pooling said at least two UCB units to produce said population of cells. The present invention relates to the use of said cells, preferably NK cells, obtainable or obtained by the process according to the invention, as a composition for therapeutic use, preferably for the treatment of cancer and chronic infectious disease.
Type:
Application
Filed:
March 9, 2015
Publication date:
March 16, 2017
Applicant:
INSTITUT NATIONAL DE LA SANTE ET DE RECHERCHE MEDICALE (INSERM)
Inventors:
Patrick HENNO, Martin VILLALBA GONZALEZ
Abstract: The present invention relates to a method of assessing a favorable or, on the contrary, an unfavorable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of cancer in the subject.
Type:
Grant
Filed:
June 2, 2009
Date of Patent:
March 14, 2017
Assignees:
INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
Type:
Grant
Filed:
September 27, 2013
Date of Patent:
March 14, 2017
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Lorraine, Cantre Hospitalier et Universitaire de Nancy (CHU), Universite Paris Diderot-Paris 7, Universite Paris Descartes
Inventors:
Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
Type:
Grant
Filed:
February 6, 2013
Date of Patent:
March 14, 2017
Assignees:
UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
Inventors:
Monique Capron, Mohamed El Nady, Jean-Frederic Colombel, Gilles Riveau